sodium channel Inhibitors
2 drugsAbout sodium channel
Sodium channels are transmembrane proteins essential for electrical signaling in excitable cells like neurons and muscle cells. They selectively allow sodium ions to flow across the cell membrane, causing rapid changes in membrane potential. This process is critical for nerve impulse transmission and muscle contraction.
Sodium channels are important drug targets due to their role in fundamental physiological processes. Currently, there is no genetic evidence directly linking sodium channels to specific diseases, but approved drugs demonstrate clinical relevance.
Two FDA-approved drugs, MEXILETINE HYDROCHLORIDE and ZINGO, target sodium channels. Both drugs are small molecules, with MEXILETINE HYDROCHLORIDE having two indications and ZINGO having one.
Top sodium channel Drugs
Two companies, SENORES PHARMS and POWDER PHARMS, have approved drugs targeting sodium channels.
Low number of players suggests relatively low barriers to entry in this space.
sodium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets sodium channel, using small molecule modality.
Explore non-small molecule modalities like antibodies to differentiate from existing drugs.
sodium channel Clinical Trials 282 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on sodium channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 24 | 8 | 2 | 75% |
| Phase 2 | 62 | 40 | 12 | 10 | 77% |
| Phase 3 | 45 | 33 | 5 | 7 | 87% |
| Phase 4 | 141 | 101 | 26 | 14 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
sodium channel Drug Approval Timeline (1995 - 1995)
The first drug was approved in 1995 and the most recent in 2007, spanning 13 years.
The approval timeline suggests a potentially saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 211 (17 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on sodium channel. A trial counts if an approved drug acting on sodium channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.